Whitehawk Therapeutics Inc
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- David J. Lennon
- Full Time Employees
- 40
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 17383 Sunset Blvd, Suite A250 Pacific Palisades CA United States of America 90272
- IPO Date
- Aug 1, 2017
- CIK
- 0001422142
- Website
- ir.whitehawktx.com
- Similar Companies
- Business
- Whitehawk Therapeutics Inc (NASDAQ:WHWK) is a clinical-stage biotechnology company focused on developing antibody-drug conjugate (ADC) therapies for difficult-to-treat cancers. Incorporated in 2007 and headquartered in Morristown, New Jersey, the company offers a three-asset ADC portfolio engineered with advanced next-generation platform technology featuring highly stable cleavable linkers and topoisomerase I inhibitor payloads; these assets target clinically validated proteins such as MUC16, SEZ6, and PTK7 that are broadly expressed in high-need tumor types including non-small cell lung, small cell lung, and ovarian cancers. The portfolio, in-licensed exclusively from WuXi Biologics, emphasizes improved therapeutic index, stability, and minimal off-target toxicity compared to first-generation ADCs, with an initial development focus on lung and gynecological indications and plans to advance all three to IND within 15 months. In March 2025, the company rebranded from Aadi Bioscience Inc, completed the sale of its Aadi Subsidiary to Kaken Pharmaceuticals for $102.4 million in cash, and secured $100 million in PIPE financing to fund ADC development and operations into 2028. These strategic moves support upcoming clinical data readouts and pipeline progression through early clinical milestones.
Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026
Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026
Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference
Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload
Whitehawk Therapeutics to Participate in the TD Cowen 7th Annual Oncology Innovation Summit
Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum
Whitehawk Therapeutics: 'Hold' On Name Change And Next Generation PTK7 ADC Targeting
Whitehawk Therapeutics Announces $87.5M Private Placement Equity Financing
Whitehawk Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
Whitehawk Therapeutics Presents Comprehensive Preclinical Data Highlighting its Next-Generation ADC Portfolio at the AACR 2026
Scott Giacobello Sells 141,600 Shares of Whitehawk Therapeutics (NASDAQ:WHWK) Stock
Whitehawk Therapeutics to Participate in Jones Trading Post-AACR Fireside Chat Series
Bryan Ball Sells 6,596 Shares of Whitehawk Therapeutics (NASDAQ:WHWK) Stock
Bryan Ball Sells 50,000 Shares of Whitehawk Therapeutics (NASDAQ:WHWK) Stock
Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as a Highly Expressed, Clinically Relevant Target for Gynecologic Cancers at SGO 2026
David James Lennon Sells 26,858 Shares of Whitehawk Therapeutics (NASDAQ:WHWK) Stock
Whitehawk Therapeutics to Highlight its Next-Generation ADC Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026
Ally Bridge Group NY LLC Takes $1.55 Million Position in Whitehawk Therapeutics, Inc. $WHWK
2,849,402 Shares in Whitehawk Therapeutics, Inc. $WHWK Purchased by Avoro Capital Advisors LLC
Whitehawk Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights